RE: Well really ---17 Dec 2016 00:02
woodford income fund comment:
"Turning to portfolio activity, we reduced the portfolio’s exposure to non-life insurance company, Hiscox, which has performed very well over a long period of time. It is a great business, in our view, with attractive long-term growth prospects and a very strong, disciplined management team. Its shares now value these positive characteristics more appropriately, however, and so we recycled part of the position into other opportunities where valuations are a bit more appealing.
These included the commencement of a new position in life insurance business, Aviva. In some respects, the investment case for Aviva is similar to that for Legal & General as both companies have good management teams and very attractive valuations, particularly in terms of yield. Aviva, although broadly similar to Legal & General, has a portfolio of different growth drivers in savings and protection markets and we deemed it attractive enough to start building a modest position.
Elsewhere, we also took advantage of unjustified share price weakness to add to our positions in AstraZeneca, Drax, and Stobart at what we consider to be very attractive valuations"